Analysts at Ladenburg Thalmann cut their price target on shares of Questcor Pharmaceuticals (NASDAQ: QCOR) from $51.00 to $46.00 in a research report issued to clients and investors on Monday. They currently have a “buy” rating on the company’s shares.
Separately, analysts at Jefferies Group (NYSE: JEF) reiterated a “buy” rating on shares of Questcor Pharmaceuticals in a research note to investors on Friday. Also, analysts at Oppenheimer (NYSE: OPY) reiterated an “outperform” rating on shares of Questcor Pharmaceuticals in a research note to investors on Thursday, January 12nd.
Shares of Questcor Pharmaceuticals opened at 36.61 on Monday. Questcor Pharmaceuticals has a one year low of $12.16 and a one year high of $45.95. The stock’s 50-day moving average is $39.0 and its 200-day moving average is $35.01. The company has a market cap of $2.288 billion and a P/E ratio of 44.59.
Pharmaceuticals (QCOR) resistance level is $45 and support level is $32.
Separately, analysts at Jefferies Group (NYSE: JEF) reiterated a “buy” rating on shares of Questcor Pharmaceuticals in a research note to investors on Friday. Also, analysts at Oppenheimer (NYSE: OPY) reiterated an “outperform” rating on shares of Questcor Pharmaceuticals in a research note to investors on Thursday, January 12nd.
Shares of Questcor Pharmaceuticals opened at 36.61 on Monday. Questcor Pharmaceuticals has a one year low of $12.16 and a one year high of $45.95. The stock’s 50-day moving average is $39.0 and its 200-day moving average is $35.01. The company has a market cap of $2.288 billion and a P/E ratio of 44.59.
Pharmaceuticals (QCOR) resistance level is $45 and support level is $32.
More Stocks News
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/
